Table 2.
Meta-analysis of SOX2 expression and prognosis in gastric cancer.
| Categories | Studies (patients) | HR (95% CI) | I2 (%) | P h | Z | P |
|---|---|---|---|---|---|---|
| OS | 10 (1321) | 1.485 (1.022–2.160)R | 88.6 | <.01 | 2.07 | .04 |
| Analysis method | ||||||
| Multivariate analysis | 5 (810) | 1.275 (0.576–2.823)R | 89.2 | <.01 | 0.60 | .55 |
| Univariate analysis | 10 (1321) | 1.606 (1.134–2.274)R | 90.1 | <.01 | 2.67 | <.01 |
| Recruitment time | ||||||
| Exceeding 2010 | 5 (638) | 1.873 (1.041–3.371)R | 89.7 | <.01 | 2.09 | .04 |
| Up to 2010 | 5 (683) | 1.180 (0.729–1.910)R | 82.9 | <.01 | 0.67 | .50 |
| Follow up period | ||||||
| >5yr | 7 (1075) | 1.642 (1.066–2.527)R | 89.5 | <.01 | 2.25 | .02 |
| ≤5 yr | 3 (246) | 1.181 (0.402–3.468)R | 90.0 | <.01 | 0.30 | .76 |
| Cutoff value | ||||||
| More than 5% of cells stained | 7 (1036) | 1.730 (1.162–2.577)R | 84.9 | <.01 | 2.70 | <.01 |
| Less than 5% of cells stained | 2 (185) | 0.625 (0.246–1.583)R | 87.4 | <.01 | 0.99 | .32 |
| Research region | ||||||
| East Asia | 8 (1045) | 1.312 (0.874–1.970)R | 90.3 | <.01 | 1.31 | .19 |
| Non-east Asia | 2 (276) | 2.790 (1.596–4.877)R | 0.0 | .43 | 3.60 | <.01 |
CI = confidence interval, HR = hazard ratio, OS = overall survival, P = P-value for statistical significance based on Z test, Ph = P-value for heterogeneity based on Q test,
R
= pooled HRs were derived from random-effect model.